DOTA-CycMSH

DOTA-CycMSH is a **radiolabeled peptide drug** that combines a DOTA chelator (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) with a cyclized α-melanocyte-stimulating hormone (α-MSH) analog[3]. It is designed to target the **melanocortin 1 receptor (MC1R)**, which is highly expressed on melanoma cells. Upon radiolabeling, such as with ^225Ac, ^111In, ^67Ga, or ^177Lu, DOTA-CycMSH functions either as a diagnostic imaging agent or as a targeted radiotherapeutic for melanoma[1][3]. Its mechanism relies on high-affinity, receptor-mediated binding to MC1R, rapid internalization into melanoma cells, and prolonged tumor retention, enabling selective imaging and/or therapy[1][3].

Other names

DOTA-modified cyclized α-melanocyte-stimulating hormoneDOTA-CycMSH